Lilly and InnoCare have entered a multi-target research and licensing collaboration potentially worth $3.35 billion to discover and develop new medicines.

Arcturus Therapeutics has agreed to acquire Belgian AI drug-discovery company myNEO, expanding its computational capabilities for mRNA medicine design and target identification.

AbbVie and Iambic have entered a multi-year collaboration to use artificial intelligence and computational drug discovery across immunology, neuroscience and oncology.

Novo Nordisk and Orbis Medicines have entered a multi-target drug-discovery partnership worth up to $1.4 billion to develop orally bioavailable macrocycle medicines for cardiometabolic disease.

Roche and Dualitas Therapeutics have entered a large-scale bispecific antibody discovery collaboration potentially worth more than $1 billion across immunology and inflammation programmes.

The non-exclusive agreement gives SignalChem access to Monod Bio’s LuxSit luciferase and NovoBodies technologies for custom research assays and protein-fusion services, extending the commercial reach of its AI-designed protein platform.

The global collaboration gives Lilly access to OmniAb’s specialist ion channel discovery and screening capabilities for an undisclosed therapeutic target and modality.

The multi-program deal pairs Aizen’s DaX AI platform with an undisclosed San Diego biotechnology company to design oral peptide therapeutics against nominated immunology and neurology targets.

The research collaboration combines Mediar’s fibrosis biology and antibody discovery capabilities with Ono’s drug development expertise to identify new treatments targeting fibro-inflammatory disease mechanisms.